Search Results - "Saag, K G"

Glucocorticoid-induced osteoporosis: 2019 concise clinical review by Adami, G., Saag, K. G.

“…Glucocorticoids remain widely used for many medical conditions, and fractures are the most serious common adverse event related to long-term glucocorticoid…”
Get full text

The clinician’s guide to prevention and treatment of osteoporosis by LeBoff, M. S., Greenspan, S. L., Insogna, K. L., Lewiecki, E. M., Saag, K. G., Singer, A. J., Siris, E. S.

“…Osteoporosis is the most common metabolic bone disease in the USA and the world. It is a subclinical condition until complicated by fracture(s). These…”
Get full text

Hip fracture trends in the United States, 2002 to 2015 by Michael Lewiecki, E., Wright, N. C., Curtis, J. R., Siris, E., Gagel, R. F., Saag, K. G., Singer, A. J., Steven, P. M., Adler, R. A.

“…Summary An analysis of United States (US) Medicare claims data from 2002 to 2015 for women aged ≥ 65 years found that age-adjusted hip fracture rates for 2013,…”
Get full text

The impact of the new National Bone Health Alliance (NBHA) diagnostic criteria on the prevalence of osteoporosis in the USA by Wright, N. C., Saag, K. G., Dawson-Hughes, B., Khosla, S., Siris, E. S.

“…Summary We evaluated the prevalence of osteoporosis using the osteoporosis diagnostic criteria developed by the National Bone Health Alliance (NBHA), which…”
Get full text

EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases by Hoes, J N, Jacobs, J W G, Boers, M, Boumpas, D, Buttgereit, F, Caeyers, N, Choy, E H, Cutolo, M, Da Silva, J A P, Esselens, G, Guillevin, L, Hafstrom, I, Kirwan, J R, Rovensky, J, Russell, A, Saag, K G, Svensson, B, Westhovens, R, Zeidler, H, Bijlsma, J W J

“…Objective:To develop evidence-based recommendations for the management of systemic glucocorticoid (GC) therapy in rheumatic diseases.Methods:The…”
Get full text

Gout epidemiology: results from the UK General Practice Research Database, 1990–1999 by Mikuls, T R, Farrar, J T, Bilker, W B, Fernandes, S, Schumacher, H R, Saag, K G

“…Objective: To examine the epidemiology of gout and gout treatment in the United Kingdom using a large national practice based population. Methods: Data from…”
Get full text

Correction to: The clinician’s guide to prevention and treatment of osteoporosis by LeBoff, M. S., Greenspan, S. L., Insogna, K. L., Lewiecki, E. M., Saag, K. G., Singer, A. J., Siris, E. S.

Get full text

Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data by Da Silva, J A P, Jacobs, J W G, Kirwan, J R, Boers, M, Saag, K G, Inês, L B S, de Koning, E J P, Buttgereit, F, Cutolo, M, Capell, H, Rau, R, Bijlsma, J W J

“…Adverse effects of glucocorticoids have been abundantly reported. Published reports on low dose glucocorticoid treatment show that few of the commonly held…”
Get full text

Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday by Curtis, J. R., Westfall, A. O., Cheng, H., Delzell, E., Saag, K. G.

“…Summary Based upon interest in a bisphosphonate drug holiday, we evaluate the risk for hip fracture after bisphosphonate discontinuation. Among women compliant…”
Get full text

Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases by van der Goes, M C, Jacobs, J W G, Boers, M, Andrews, T, Blom-Bakkers, M A M, Buttgereit, F, Caeyers, N, Choy, E H, Cutolo, M, Da Silva, J A P, Guillevin, L, Holland, M, Kirwan, J R, Rovensky, J, Saag, K G, Severijns, G, Webber, S, Westhovens, R, Bijlsma, J W J

“…To explore perspectives among patients and rheumatologists on glucocorticoid (GC) therapy and European League Against Rheumatism (EULAR) recommendations on the…”
Get more information

Vertebroplasty and kyphoplasty are associated with an increased risk of secondary vertebral compression fractures: a population-based cohort study by Mudano, A. S, Bian, J, Cope, J. U, Curtis, J. R, Gross, T. P, Allison, J. J, Kim, Y, Briggs, D, Melton, M. E, Xi, J, Saag, K. G

“…Summary To better understand the risk of secondary vertebral compression fracture (VCF) following a vertebroplasty or kyphoplasty, we compared patients treated…”
Get full text

Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD) by Mikuls, T. R., Farrar, J. T., Bilker, W. B., Fernandes, S., Saag, K. G.

“…Objectives: To examine adherence to validated quality indicators assessing the quality of allopurinol use in the treatment of gout and asymptomatic…”
Get full text

Patient's experience with subcutaneous and oral methotrexate for the treatment of rheumatoid arthritis by Curtis, J R, Xie, F, Mackey, D, Gerber, N, Bharat, A, Beukelman, T, Saag, K G, Chen, L, Nowell, B, Ginsberg, S

“…Despite the prominent position of methotrexate (MTX) in Rheumatoid Arthiris (RA) therapeutics, its real-world effectiveness may be influenced by a relative…”
Get full text

Failure to perceive increased risk of fracture in women 55 years and older: the Global Longitudinal Study of Osteoporosis in Women (GLOW) by Siris, E. S, Gehlbach, S, Adachi, J. D, Boonen, S, Chapurlat, R. D, Compston, J. E, Cooper, C, Delmas, P, Díez-Pérez, A, Hooven, F. H, LaCroix, A. Z, Netelenbos, J. C, Pfeilschifter, J, Rossini, M, Roux, C, Saag, K. G, Sambrook, P, Silverman, S, Watts, N. B, Wyman, A, Greenspan, S. L

“…Summary We compared self-perception of fracture risk with actual risk among 60,393 postmenopausal women aged ≥55 years, using data from the Global Longitudinal…”
Get full text

Clinical and demographic factors associated with fractures among older Americans by Taylor, A. J., Gary, L. C., Arora, T., Becker, D. J., Curtis, J. R., Kilgore, M. L., Morrisey, M. A., Saag, K. G., Matthews, R., Yun, H., Smith, W., Delzell, E.

“…Summary Medicare claims data were used to investigate associations between history of previous fractures, chronic conditions, and demographic characteristics…”
Get full text

Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design by Hooven, F. H, Adachi, J. D, Adami, S, Boonen, S, Compston, J, Cooper, C, Delmas, P, Diez-Perez, A, Gehlbach, S, Greenspan, S. L, LaCroix, A, Lindsay, R, Netelenbos, J. C, Pfeilschifter, J, Roux, C, Saag, K. G, Sambrook, P, Silverman, S, Siris, E, Watts, N. B, Anderson, F. A. Jr

“…Summary The Global Longitudinal study of Osteoporosis in Women (GLOW) is a prospective cohort study involving 723 physicians and 60,393 women subjects >=55…”
Get full text

Estimated prevalence and patterns of presumed osteoporosis among older Americans based on Medicare data by Cheng, H, Gary, L. C, Curtis, J. R, Saag, K. G, Kilgore, M. L, Morrisey, M. A, Matthews, R, Smith, W, Yun, H, Delzell, E

“…Introduction Estimates of osteoporosis (OP) prevalence based on bone mineral density testing and fracture occurrence may be imprecise for small demographic…”
Get full text

Sex differences in gout epidemiology: evaluation and treatment by Harrold, L R, Yood, R A, Mikuls, T R, Andrade, S E, Davis, J, Fuller, J, Chan, K A, Roblin, D, Raebel, M A, Von Worley, A, Platt, R, Saag, K G

“…Background: Little is known about the characteristics, evaluation and treatment of women with gout. Objective: To examine the epidemiological differences and…”
Get full text

Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis by Hughes, L B, Beasley, T M, Patel, H, Tiwari, H K, Morgan, S L, Baggott, J E, Saag, K G, McNicholl, J, Moreland, L W, Alarcón, G S, Bridges, S L

“…Background: The anti-folate drug methotrexate (MTX) is commonly used to treat rheumatoid arthritis. Objective: To determine the allele frequencies of five…”
Get full text

Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-α antagonists by Curtis, J. R., Kramer, J. M., Martin, C., Saag, K. G., Patkar, N., Shatin, D., Burgess, M., Xie, A., Braun, M. M.

“…Objectives. New onset heart failure (HF) has been associated with the use of TNF-α antagonists etanercept and infliximab based upon spontaneous adverse event…”
Get full text